Opinion

The Most Interesting Activity in ADC Development is no Longer Happening in Traditional Formats

Engineering the Future of Cancer Care: How Next-Generation Antibody-Drug Conjugates (ADCs) Are Shaping Oncology and Beyond

Acute Myeloid Leukemia (AML) is a heterogeneous and highly aggressive hematologic malignancy characterized by a wide range of cytogenetic and molecular abnormalities that define distinct disease subgroups.

3rd Antibody-Drug Conjugate (ADC)  in Boston, MA, brought together a group of diverse yet deeply specialized experts who shared their knowledge, clinical insights, and technical experience with remarkable openness and clarity.

The Opportunity to go Beyond “chemo on a stick” ADCs

Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer therapeutics, offering significant advancements over traditional treatments. The global ADC market is projected to reach $11.29 billion in 2023, with an estimated compound annual growth rate (CAGR) of 9.2% between 2024 and 2030, reflecting substantial economic and scientific interest in this field

Finding Synergies in Combining ADCs with Multispecific Antibodies

20-Hour Conjugation Bottlenecks – Confronting ADC Development Challenges with CDMOs

Required adaptations to clinical trial design and execution, implemented during the COVID-19 pandemic, have put a new focus on the development of patient-focused, decentralized...

One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He...